Categories:

New mint Lesion 3.4 Software presented at RSNA 2017

With mint Lesion 3.4, reproducible assessment and structured reporting of significant image observations are easier than ever. Numerous improvements…

ESOI/EORTC Workshop in Barcelona: Participants practice tumour response assessment using mint Lesion™

The autumn workshop of the European Society of Oncological Imaging (ESOI) and the European Organisation for Research and Treatment of Cancer (EORTC)…

Mint Medical showcases MSK-Prototype at IMR 2017 in Hamburg

Mint Medical was one of the sponsors of the first Intensive course Musculoskeletal Radiology (IMR) which took place on September 8th and 9th 2017 in…

A look ahead with mint Lesion 3.3

Mint Medical is pleased to announce the recent release of their software product version 3.3 of mint Lesion™ which was completed during recent weeks.…

New iRECIST Oncologic Response Criteria already in clinical use at the University Medical Center – Tübingen, Germany

Shortly following the release of the new iRECIST- oncologic response criteria (Lancet Oncology, March 2017) the University Medical Center in Tübingen,…

Mrs. Kelie Luby joins Mint Medical's team

Mrs. Kelie Luby will join Mint Medical’s team from January 2017 as new Vice President Clinical Trials Software and will be introduced at the upcoming…

Novel oncologic therapy response criteria (iRECIST and more)

Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and…

Customized templates in mint Lesion 3.3

mint Lesion™ 3.3 features a novel data and knowledge modelling core that enables you to customize read procedures and reporting templates – or design…

Data Analytics and Instant-Trial Research

Context-driven read procedures in mint Lesion™ facilitate the generation of well-structured data on a large scale. At RSNA 2016, Mint Medical presents…